A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.

Cohen JB, Maddocks KJ, Huang Y, Christian BA, Jaglowski SM, Flowers CR, Blum KA
Leuk Lymphoma 58 1-2 01/01/2017

Abstract

Full Text